StockTipsArenaBeta

BUY Zydus Lifesciences Limited — Akshay Bhagwat, JM Financial

BUYZydus Lifesciences Limited
Zydus Lifesciences share price target & all analyst calls

byAkshay Bhagwat, JM FinancialHorizon: NA (inferred Swing (≤2wk))8 Jun 2026via ET Now

Entry₹1,087.6Inferred
Target₹1,130
Total upside +3.90% (call closed)
Stop loss₹1,060-2.54% risk
Exit₹1,06017 Jun 2026, 12:00 pm
Stop-loss hit-2.54%
Follow Akshay Bhagwat for new calls(23% target hit, 115 closed calls)Get alertsWatch ZYDUSLIFE for new buy/sell callsGet alertsSee 144 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 23 Oct, 2:37 pm IST
3 supporting1 neutral0 opposing
Supports the BUY call (3)

Zydus Lifesciences Limited announces the completion of the merger of its subsidiary Zara Merger Sub Inc. with Assertio Holdings Inc. Assertio has now become a wholly owned subsidiary of Zydus Lifescie

BSE · Company Update·16 Jun · today

(opens in new tab)

Zydus Lifesciences Ltd announced the successful completion of its acquisition of Assertio Holdings.

BSE · Company Update·16 Jun · today

(opens in new tab)

Zydus Lifesciences Limited's New Drug Application (NDA) for Saroglitazar to treat Primary Biliary Cholangitis (PBC) has been granted Priority Review by the US FDA.

NSE · Press Release·28 May · 3w ago

(opens in new tab)
Neutral / worth noting (1)

Zydus Lifesciences Ltd has issued an addendum to its public announcement regarding the buyback of equity shares.

BSE · Company Update·27 May · 3w ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Zydus Lifesciences

All analyst calls on Zydus Lifesciences

More from Akshay Bhagwat, JM Financial

Every call and its outcome